COMPANY

L2 Diagnostics

l2diagnostics.com ↗ · New England

Keywords: From press sources:vaccine infectious disease cutaneous lupus erythematosus

Profile checked Oct 10, 2026

50NIH grants

NIH awards 50

Annual award amounts. Total $58.1M.

Sep 19, 2026 NIH award 1R41AR087258-01A1 FY2026: $323,090 awarded for that fiscal year; activity R41 (STTR); PI KARATEPE, KUTAY; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A novel therapeutic, L2ASOCLE, for treatin source ↗
Aug 28, 2026 NIH award 5R41AI195230-02 FY2026: $300,000 awarded for that fiscal year; activity R41 (STTR); PI CHUANG, YU-MIN; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. PfAg, a multivalent peptide vaccine against m source ↗
Aug 19, 2026 NIH award 5R43AI188960-02 FY2026: $274,710 awarded for that fiscal year; activity R43 (SBIR); PI SUTHERLAND, ALAN GORDON; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A Point of Care Test for Babesia mic source ↗
Aug 14, 2026 NIH award 5R41AI195232-02 FY2026: $300,065 awarded for that fiscal year; activity R41 (STTR); PI CHUANG, YU-MIN; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A vaccine targeting mosquito metabolic pathwa source ↗
Sep 23, 2025 NIH award 1R41AI188982-01A1 FY2025: $281,786 awarded for that fiscal year; activity R41 (STTR); PI MARIN LOPEZ, ALEJANDRO; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A viral vector-based vaccine to ind source ↗
Sep 23, 2025 NIH award 1R41AI195232-01 FY2025: $299,644 awarded for that fiscal year; activity R41 (STTR); PI CHUANG, YU-MIN; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A vaccine targeting mosquito metabolic pathwa source ↗
Sep 21, 2025 NIH award 1R43AI188960-01 FY2025: $293,142 awarded for that fiscal year; activity R43 (SBIR); PI SUTHERLAND, ALAN GORDON; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A Point of Care Test for Babesia mic source ↗
Sep 15, 2025 NIH award 1R41AI195230-01 FY2025: $299,954 awarded for that fiscal year; activity R41 (STTR); PI CHUANG, YU-MIN; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. PfAg, a multivalent peptide vaccine against m source ↗
Jul 15, 2025 NIH award 5R41AI186794-02 FY2025: $299,969 awarded for that fiscal year; activity R41 (STTR); PI FIKRIG, EROL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. The mosquito salivary protein AgBR1 as vaccine source ↗
Jul 2, 2025 NIH award 5R41AI186833-02 FY2025: $299,933 awarded for that fiscal year; activity R41 (STTR); PI FIKRIG, EROL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A novel therapeutic for Lyme arthritis based on source ↗
May 19, 2025 NIH award 5R41AI184218-02 FY2025: $299,862 awarded for that fiscal year; activity R41 (STTR); PI ANTHONY, KAREN G.; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. Delivery of a candidate AgTRIOVx malaria v source ↗
Apr 24, 2025 NIH award 5R41AI179587-02 FY2025: $299,250 awarded for that fiscal year; activity R41 (STTR); PI NARASIMHAN, SUKANYA; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A Multivalent mRNA Vaccine to Prevent Tr source ↗
2025 NIH contract (government contract; not a grant and not an investment round) 75N93025C00024-0-9999-1 FY2025: $599,471 awarded for that fiscal year; activity N43 (OTHER_NIH); PI ANTHONY, KAREN G.; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. Therape source ↗
2025 NIH contract (government contract; not a grant and not an investment round) 75N93025C00004-0-9999-1 FY2025: $300,000 awarded for that fiscal year; activity N01 (OTHER_NIH); PI LEDIZET, MICHEL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. NOVEL DIA source ↗
Jul 31, 2024 NIH award 5R42AI142846-05 FY2024: $980,219 awarded for that fiscal year; activity R42 (STTR); PI FIKRIG, EROL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A novel vaccine against mosquito-borne Zika vir source ↗
Jul 17, 2024 NIH award 1R41AI186794-01 FY2024: $299,969 awarded for that fiscal year; activity R41 (STTR); PI FIKRIG, EROL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. The mosquito salivary protein AgBR1 as vaccine source ↗
Jul 8, 2024 NIH award 1R41AI186833-01 FY2024: $299,933 awarded for that fiscal year; activity R41 (STTR); PI FIKRIG, EROL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A novel therapeutic for Lyme arthritis based on source ↗
May 28, 2024 NIH award 1R41AI184218-01 FY2024: $299,878 awarded for that fiscal year; activity R41 (STTR); PI ANTHONY, KAREN G.; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. Delivery of a candidate AgTRIOVx malaria v source ↗
Apr 29, 2024 NIH award 1R41AI179587-01A1 FY2024: $298,362 awarded for that fiscal year; activity R41 (STTR); PI NARASIMHAN, SUKANYA; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A Multivalent mRNA Vaccine to Prevent source ↗
Jul 21, 2023 NIH award 5R42AI142846-04 FY2023: $979,482 awarded for that fiscal year; activity R42 (STTR); PI FIKRIG, EROL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A novel vaccine against mosquito-borne Zika vir source ↗
Aug 18, 2022 NIH award 2R42AI142846-03 FY2022: $988,360 awarded for that fiscal year; activity R42 (STTR); PI FIKRIG, EROL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A novel vaccine against mosquito-borne Zika vir source ↗
Jul 7, 2022 NIH award 5R41AI157014-02 FY2022: $299,514 awarded for that fiscal year; activity R41 (STTR); PI NARASIMHAN, SUKANYA; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A therapeutic for Lyme disease based on source ↗
May 11, 2022 NIH award 5R44AI136118-04 FY2022: $692,082 awarded for that fiscal year; activity R44 (SBIR); PI LEDIZET, MICHEL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. An antigen-detection assay to diagnose Babes source ↗
Aug 4, 2021 NIH award 1R41AI157014-01A1 FY2021: $299,514 awarded for that fiscal year; activity R41 (STTR); PI NARASIMHAN, SUKANYA; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. A therapeutic for Lyme disease based o source ↗
May 21, 2021 NIH award 5R41AI152904-02 FY2021: $293,886 awarded for that fiscal year; activity R41 (STTR); PI LEDIZET, MICHEL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. Vaccination against Zika virus infection usi source ↗
May 10, 2021 NIH award 5R44AI136118-03 FY2021: $692,082 awarded for that fiscal year; activity R44 (SBIR); PI LEDIZET, MICHEL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. An antigen-detection assay to diagnose Babes source ↗
Jun 23, 2020 NIH award 5R41AI145778-02 FY2020: $296,626 awarded for that fiscal year; activity R41 (STTR); PI NARASIMHAN, SUKANYA; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. Targets of Acquired Tick-Resistance As A source ↗
Jun 22, 2020 NIH award 2R44AI136118-02 FY2020: $692,082 awarded for that fiscal year; activity R44 (SBIR); PI LEDIZET, MICHEL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. An antigen-detection assay to diagnose Babes source ↗
Jun 16, 2020 NIH award 1R41AI152904-01A1 FY2020: $299,200 awarded for that fiscal year; activity R41 (STTR); PI LEDIZET, MICHEL; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. Vaccination against Zika virus infection u source ↗
Jun 10, 2020 NIH award 5R43AI148228-02 FY2020: $285,676 awarded for that fiscal year; activity R43 (SBIR); PI ANTHONY, KAREN G.; recipient as written: L2 DIAGNOSTICS, LLC, NEW HAVEN, CT. Development of A Narrow Spectrum Anti-Tube source ↗

Funding and NIH signals

NIH award NIH awarded $323K (STTR Phase I 1R41AR087258-01A1, new, notice Sep 19, 2026); 4 NIH awards totaling $1.2M in the last 12 months. NIH RePORTER 1R41AR087258-01A1 (Sep 19, 2026)
Evidence (4 events)
- Sep 19, 2026 · NIH RePORTER 1R41AR087258-01A1
  Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 1R41AR087258-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 323090; Administering IC: National Institute of Arthritis and Musculoskeletal and Skin Diseases; Project title: A novel therapeutic, L2ASOCLE, for treating cutaneous lupus erythematosus (CLE); Organization type: Domestic For-Profits
- Aug 28, 2026 · NIH RePORTER 5R41AI195230-02
  Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 5R41AI195230-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: PfAg, a multivalent peptide vaccine against malaria; Organization type: Domestic For-Profits
- Aug 19, 2026 · NIH RePORTER 5R43AI188960-02
  Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 5R43AI188960-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-19; FY total cost (award amount): 274710; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Point of Care Test for Babesia microti; Organization type: Domestic For-Profits
- Aug 14, 2026 · NIH RePORTER 5R41AI195232-02
  Organization: L2 DIAGNOSTICS, LLC; City/State: NEW HAVEN, CT; Project number: 5R41AI195232-02; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-08-14; FY total cost (award amount): 300065; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A vaccine targeting mosquito metabolic pathways to eradicate malaria; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals